nach oben

Inflammopharmacology

Erschienen in:

01.02.2010 | Research Article

Population-based normative values for the Western Ontario and McMaster (WOMAC^®) osteoarthritis index and the Australian/Canadian (AUSCAN) hand osteoarthritis index functional subscales

verfasst von: Nicholas Bellamy, C. Wilson, J. Hendrikz

Erschienen in: Inflammopharmacology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

To develop age- and gender-specific normative values for the physical function subscales of the WOMAC^® and AUSCAN Indices.

Methods

A scannable survey questionnaire capable of capturing WOMAC^® and AUSCAN Index and demographic information was developed, pre-tested, and distributed to a stratified random sample of 24,000 members of the Australian general public generated by the Australian Electoral Commission (AEC).

Results

Age- and gender-specific WOMAC^® and AUSCAN normative values were estimated based on approximately 5,500 subjects. Age-related differences were noted at the subscale level. In general, disability increased with age for all items and both Indices.

Conclusions

Normative values provide opportunity for benchmarking the health status of individuals against their age- and gender-matched peers in the general population. These normative values provide unique opportunities, for using the WOMAC^® and AUSCAN Indices in benchmarking applications, in both clinical practice and research.

Australian Bureau of Statistics (ABS) (2009) http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Seifa_entry_page

Bellamy N (2005) The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clin Exp Rheumatol 23(Suppl 39):148–153

Bellamy N (2006) AUSCAN User guide III. The University of Queensland, Brisbane, Australia pp 1–20. www.auscan.org

Bellamy N (2008a) Principles of outcome assessment. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 4th edn. Elsevier, Philadelphia, pp 11–20

Bellamy N (2008b) WOMAC^® User guide IX. The University of Queensland, Brisbane, Australia pp 1–76. www.womac.org

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt L (1988a) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMed

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt L (1988b) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J Orthop Rheumatol 1:95–108

Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M (1997) Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development in OMERACT III. J Rheumatol 24:799–802PubMed

Bellamy N, Kaloni S, Pope J, Coulter K, Campbell J (1998) Quantitative rheumatology: a survey of outcome measurement procedures in routine rheumatology outpatient practice in Canada. J Rheumatol 25:852–858PubMed

Bellamy N, Muirden KD, Brooks PM, Barraclough D, Tellus MM, Campbell J (1999) Quantitative rheumatology: a survey of outcome measurement procedures in routine rheumatology outpatient practice in Australia. J Rheumatol 26:1593–1599PubMed

Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hobby K, Roth JH, MacDermid JC (2002a) Dimensionality and clinical importance of pain and disability in hand osteoarthritis: development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. Osteoarthr Cartil 10(11):855–862CrossRefPubMed

Bellamy N, Campbell J, Haraoui B, Gerecz-Simon E, Buchbinder R, Hobby K, MacDermid JC (2002b) Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthr Cartil 10(11):863–869CrossRefPubMed

Bellamy N, Krupa D, Markind JE, Reicin AS, Malmstrom K (2004a) WOMAC 20, 50, 70 response levels in patients treated with Rofecoxib for osteoarthritis. Osteoarthr Cartil 12(Suppl B):S70

Bellamy N, Krupa D, Markind JE, Reicin AS, Malmstrom K (2004b) Prevalence of patients with low intensity pain symptom severity states during treatment with rofecoxib and Ibuprofen for osteoarthritis. Osteoarthr Cartil 12(Suppl B):S69

Bellamy N, Bell M, Goldsmith C, Pericak D, Walker V, Raynauld J-P, Torrance G, Tugwell P, Polisson R (2005) Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 64:881–885CrossRefPubMed

Bellamy N, Wilson C, for the REFLECT Study Group (2007a) International estimation of Minimum Clinically Important Improvement (MCII75): the reflect study. Int Med J 37(Suppl 2):A36

Bellamy N, Bell MJ, Pericak D, Goldsmith CH, Torrance GW, Raynauld J-P, Walker V, Tugwell P, Polisson R (2007b) BLISS Index for analysing knee osteoarthritis trials data. J Clin Epidemiol 60:124–132CrossRefPubMed

Bellamy N, Wilson C, for the REFLECT Study Group (2007c) International estimation of Patient Acceptable Symptom Severity (PASS75): the reflect study. Int Med J 37(Suppl 2):A36

Bellamy E, Wilson C, Bellamy N (2009a) Osteoarthritis Measurement in Routine Rheumatology Outpatient Practice (OMIRROP) in Australia: a survey of practice style, instrument use, responder criteria and state-attainment criteria. J Rheumatol 36(5):1049–1055CrossRefPubMed

Bellamy N, Bell MJ, Pericak D, Goldsmith CH, Lee S, Maschio M, Raynauld J-P, Torrance GW, Tugwell P (2009b) BLISS Index using WOMAC Index detects between-group differences at low-intensity symptom states in osteoarthritis. J Clin Epidemiol. doi: 10.1016/j.jclinepi.2009.07.011

Bowling A, Bond M, Jenkinson C, Lamping DL (1999) Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Health Survey. J Public Health Med 21(3):255–270CrossRefPubMed

Brooks PM (2006) The burden of musculoskeletal disease: a global perspective. Clin Rheumatol 25(6):778–781CrossRefPubMed

Dougados M, LeClaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD (2000) Special article: response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthr Cartil 8(6):395–403CrossRefPubMed

Dworkin R, Turk D, Farrar J, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1–2):9–19CrossRefPubMed

Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N (2000) Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 27(11):2635–2641PubMed

European Agency for the Evaluation of Medicinal Products (EMEA) (1998) In: Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis, pp 1–6

Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P (2004) Normative values for the Health Assessment Questionnaire Disability Index. Arthritis Rheum 50(3):953–960CrossRefPubMed

Kvien TK, Zhang YZ, Nicols M, Dougados M, Podrebarac TA, Bellamy N (2007) Response and state-attainment criteria in hand OA: analyses from a placebo-controlled clinical trial of CRX-102, a novel synergistic combination therapy. Ann Rheum Dis 66(Suppl II):501

Lybrand S, Bellamy N (2002) Impact of OARSI-OMERACT recommendations for outcome measurement on clinical practice: a 5 year reassessment. NZA-ARA Combined Scientific Conference, Christchurch, New Zealand, May 2002. Abstract Book, p 112

Maheu E, Altman RD, Bloch DA, Doherty M, Hochberg M, Mannoni A, Punzi L, Spector T, Verbruggen G; Osteoarthritis Research Society International Hand OA Task Force, Carr A, Cicuttini F, Dreiser RL, Haraoui BP, Hart D, Pelletier JP, Ramonda R, Rovati L (2006) Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International. Osteoarthr Cartil 14(4):303–322

Osteoarthritis Research Society (OARS) Task force report: design and conduct of clinical trials of patients with osteoarthritis: recommendations from a Task Force of the Osteoarthritis Research Society (1996) Osteoarthr Cartil 4:217–243

Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M (2004) OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 12:389–399CrossRefPubMed

SPSS PASW version 17.0.2 (2009). SPSS Inc. Chicago, IL, USA

Tubach F, Baron G, Ravaud P, Falissard B, Longeart I, Bombardier C, Felson D, van der Heijde D, Hochberg M, Bellamy N, Dougados M (2003) Evaluation of clinically relevant changes and states in symptomatic outcome variables in osteoarthritis. Ann Rheum Dis 7(62)(Suppl 1):276

Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson DT, Hochberg MC, van der Heijde D, Dougados M (2005a) Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement. Ann Rheum Dis 64(1):29–33CrossRefPubMed

Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson DT, Hochberg MC, van der Heijde D, Dougados M (2005b) Evaluation of clinically relevant states in patient-reported outcomes in knee and hip osteoarthritis: the Patient Acceptable Symptom State. Ann Rheum Dis 64(1):34–37CrossRefPubMed

Turk DC, Dworkin RH, Allen RR, Bellamy N et al (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3):337–345CrossRefPubMed

US Department of Health and Human Services Food and Drug Administration (2006) Guidance for industry–patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/cder/guidance/index.htm

US Food and Drug Administration (1999) Guidance for industry: clinical development programs for drugs, devices and biological products intended for the treatment of osteoarthritis (OA), pp 1–9

Titel: Population-based normative values for the Western Ontario and McMaster (WOMAC®) osteoarthritis index and the Australian/Canadian (AUSCAN) hand osteoarthritis index functional subscales
verfasst von: Nicholas Bellamy
C. Wilson
J. Hendrikz
Publikationsdatum: 01.02.2010
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammopharmacology / Ausgabe 1/2010
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-009-0021-0

Springer Medizin

Abstract

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Klaus Ley (ed): Adhesion molecules: function and inhibition (Series: PIR—Progress in Inflammation Research)

Biochemical observations relating to oxidant stress injury in Chernobyl clean-up workers (“liquidators”) from Latvia

l-Arginine reverses cigarette-induced reduction of fractional exhaled nitric oxide in asthmatic smokers

Potassium humate inhibits carrageenan-induced paw oedema and a graft-versus-host reaction in rats

Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation

Adriano G. Rossi and Deborah A. Sawatzky (eds): The resolution of inflammation (Series: PIR—Progress in Inflammation Research)